Patients with Celiac Disease at Higher Risk for Lymphoma?

According to a new study, certain subgroups of patients with celiac disease are at a higher risk for lymphoproliferative disorders.

As per the results attained by Lori A. Leslie and colleagues from Columbia University in New York City, older patients who had developed celiac disease appeared more prone to coming down with lymphoproliferative disorder. They reported symptoms like abdominal pain and diarrhea appearing around the same period of time the diagnosis was made.

"It's important to differentiate between these subtypes because there are major differences in prognosis and treatment," Leslie said.

In order to come to their conclusions, Leslie and her fellow researchers conducted a retrospective study taking into account 1,281 patients treated for celiac disease. The time range for cases was 30 years, and 35 cases were identified with various sorts of for lymphoproliferative disorders.

To be able to compare the rate of occurrences in their case studies with those of the general population, researchers utilized the Surveillance, Epidemiology and End Result (SEER) database.

They found a total of 29 cases of non-Hodgkin’s lymphoma, and five cases of chronic lymphocytic leukemia.

In the non-Hodgkin’s lymphoma group, 11 were enteropathy associated T-cell lymphomas, four peripheral T-cell lymphomas, and 14 B-cell lymphomas.

"Patients diagnosed with celiac disease after age 50, who initially present with diarrhea and/or abdominal pain, are at increased risk and may need routine follow up and surveillance for the development of lymphoma," Leslie concluded

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap